Norvégia - norvég - Statens legemiddelverk

ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 125 mikrog

Norvégia - norvég - Statens legemiddelverk

ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 137 mikrog

Norvégia - norvég - Statens legemiddelverk

ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 150 mikrog

Norvégia - norvég - Statens legemiddelverk

ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 175 mikrog

Norvégia - norvég - Statens legemiddelverk

ibsa farmaceutici italia s.r.l. - levotyroksinnatrium - mikstur, oppløsning i endosebeholder - 200 mikrog

Norvégia - norvég - Adama

adama - pirimikarb - insektmiddel

Európai Unió - norvég - EMA (European Medicines Agency)

csl behring gmbh - etranacogene dezaparvovec - hemofili b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

Norvégia - norvég - Ecolab

ecolab deutschland gmbh -

Európai Unió - norvég - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastiske midler - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Európai Unió - norvég - EMA (European Medicines Agency)

helsinn birex pharmaceuticals ltd. - palonosetron hydroklorid - vomiting; cancer - antiemetika og antinauseants, , serotonin (5ht3) antagonister - aloxi er indisert hos voksne:forebygging av akutt kvalme og oppkast forbundet med svært emetogenic kreft, kjemoterapi,forebygging av kvalme og oppkast forbundet med moderat emetogenic kreft kjemoterapi. aloxi er angitt i paediatric pasienter 1 måneders alder og voksne:forebygging av akutt kvalme og oppkast forbundet med svært emetogenic kreft kjemoterapi og forebygging av kvalme og oppkast forbundet med moderat emetogenic kreft kjemoterapi.